Arvinas Inc
NASDAQ:ARVN
Arvinas Inc
Operating Income
Arvinas Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Arvinas Inc
NASDAQ:ARVN
|
Operating Income
-$401.5m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$24.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$10.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-5%
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$11.3B
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
See Also
What is Arvinas Inc's Operating Income?
Operating Income
-401.5m
USD
Based on the financial report for Dec 31, 2023, Arvinas Inc's Operating Income amounts to -401.5m USD.
What is Arvinas Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-56%
Over the last year, the Operating Income growth was -53%. The average annual Operating Income growth rates for Arvinas Inc have been -48% over the past three years , -56% over the past five years .